Compare MPV & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | SENS |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 301.2M |
| IPO Year | N/A | 2014 |
| Metric | MPV | SENS |
|---|---|---|
| Price | $16.50 | $5.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 12.1K | ★ 828.5K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | $9.55 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $15.65 | $0.41 |
| 52 Week High | $21.00 | $8.75 |
| Indicator | MPV | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 37.96 |
| Support Level | $15.91 | $5.40 |
| Resistance Level | $17.57 | $5.94 |
| Average True Range (ATR) | 0.49 | 0.40 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 11.72 | 8.33 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.